Article
Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2022
van Veelen Ard, Gulikers Judith, Hendriks Lizza E L, Dursun Safiye, Ippel Juanita, Smit Egbert F, Dingemans Anne-Marie C, van Geel Robin, Croes Sander
Abstract excerpt
INTRODUCTION: Exposure to osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treatment of non-small cell lung cancer (NSCLC) and a sensitizing EGFR mutation, can be substantially below average. We evaluated whether plasma levels could be boosted by co-administration of cobicistat, a strong Cytochrome P450 3A-inhibitor. METHODS: This was a pharmacokinetic,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.